MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER

Size: px
Start display at page:

Download "MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER"

Transcription

1 MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners Grand Rounds October 11, 2017

2 Disclosures One time lecture sponsored by Indivior about overlap of pain and opioid dependence without mention of medication for which I received honorarium.

3 Learning Objectives Explain how pain and opioid use disorder (OUD) activate the same neurobiological pathways in the brain Recognize that differentiating opioid use disorder from pain is a complex task Identify key features of opioid use disorder Identify ways to improve pain treatment in patients with opioid use disorders

4 CASE 35 yo female with chronic daily migraine and diffuse myofascial pain who has been prescribed opioids for 5 years after the birth of her daughter. The patient has severe depression and anxiety, chronic nausea, history of adverse childhood experience (neglect as a child), and obesity. She is a stay at home mother to her 2 children, but frequently has to put the children in daycare because she can not care for them when she has severe migraines. She is also prescribed chronic high dose benzodiazepines by a psychiatrist. She has been cited by the hospital as a frequent utilizer of services due to >10 ED visits in a year for nausea, vomiting, and severe migraine. The patient has a history of losing her opioid prescription, obtaining opioids from more than one provider, being allergic to most other pain medication options, missing appointments with her outpatient providers, and frequently asking for opioid dose increases.

5 Case: Thought Questions Does this patient have pain? Does this patient have an opioid use disorder? What factors place this patient at risk for an opioid use disorder? What can you do to help this patient?

6 Sleep Disturbance Secondary Physical Problems Substance Misuse Pain OUD Anxiety Depression PTSD Functional Disabilities Cognitive Distortions Increased Stresses When Opioid use disorder and pain co-occur they may reinforce one another. Need to address both to successfully treat pain, but OUD will always prevail.

7 What is the underlying neurobiological mechanism that explains the complex interaction between pain and opioid use disorder?

8 Understanding Reward and Emotion in Chronic Pain Reward learning processes may contribute to persistence and amplification of pain SBP = subacute back pain CBP = chronic back pain Hashmi JA et al, 2013

9 The Reward System in Pain & Substance Use Disorder A Quick Decision-Making Process: 1. Dopamine neurons from Ventral Tegmental Area (VTA) estimate value of reward/relief-seeking opportunity 2. Nucleus Accumbens (NAc) listens, makes decision to proceed 3. Frontal cortex also receives information from VTA, can inhibit NAc, but is slow and may be impaired ** The larger the dopamine input, the more likely you are to do that behavior

10 So What s the Problem? The reward system is crucial for survival; if out of balance, it takes over: impulsivity, search for immediate gratification, unable to tolerate distress Addictive drugs and search for pain relief can dump tons of dopamine into these circuits Addictive drugs increase activity in these neurons, or prolong actions of neurotransmitters they release New research show pain relief activates these neurons to drive habitual pain relief seeking Trafton, 2015

11 Reward Transmitters Implicated in the Motivational Effects of Drugs of Abuse Positive Hedonic Effects Dopamine Opioid Peptides Serotonin GABA Negative Hedonic Effects of Withdrawal Dopamine dysphoria Opioid Peptides pain Serotonin dysphoria GABA anxiety, panic attacks Koob, Volkow, Neuropsychopharmacology, 2010.

12 Anti-Reward Transmitters Implicated in the Motivation Effects of Drugs of Abuse Positive Hedonic Effects: The Dark Side of Addiction Dynorphin dysphoria Corticotropin-Releasing Factor (CRF) stress Norepinephrine stress These are ACTIVATED in amygdala and ventral striatum during withdrawal Koob, Volkow, Neuropsychopharmacology, 2010.

13 Summary Coupled with complex social, psychological, and biological stresses, certain people can be primed for development of severe chronic, complex pain and opioid use disorder Both substance use disorder (SUD) and pain-relief seeking behaviors activate, and over-stress, the reward system In both SUD and pain, when the reward system is over-activated, anti-reward neurotransmitters in the limbic system are enhanced, causing stress, negative affect, impulsivity, inducing compulsive behaviors to alleviate feeling lousy In both SUD and chronic pain, the executive function of the pre-frontal cortex is impaired, unable to exert control over ventral striatum and limbic system, preventing activities that promote recovery

14 Implications for Chronic Pain All about dysregulated dopamine People with dysregulated dopamine systems are more likely to develop chronic pain: Acute injury chronic pain Drugs that increase dopamine (i.e. opioids) chronic pain Smokers and people given high dose opioids after injury chronic pain even after injury heals Trafton, 2015

15 Other Implications for Pain The addicted brain may amplify pain to justify a substance it craves Alternating withdrawal and intoxication can physiologically drive pain (sympathetic and psychomotor activation) Intoxication may mask pain and permit recurrent injury or overuse Intoxication impairs adherence to treatment plan

16 Learning Objectives Explain how pain and opioid use disorder (OUD) activate the same neurobiological pathways in the brain Recognize that differentiating opioid use disorder from pain is a complex task Identify key features of opioid use disorder Identify ways to improve pain treatment in patients with opioid use disorders

17 Opioid Use Disorder in Clinical Practice The 4 C s Loss of Control Compulsive use Continued use despite harms Craving Savage SR, et al. J Pain Symptom Manage. 2003;26:

18 Features of Opioid Use Disorder Inconsistent health care use patterns missed appointments, lack of engagement with non-medication treatments, lack of follow through with recommendations Illicit drug use Problematic medication behavior (escalating doses, early refills) Family concerns about use Functional stagnation, loss of roles Extreme difficulty with even a slow opioid taper Signs/symptoms of drug use (e.g., intoxication, overdose, track marks) Implications Concern comes from the pattern or the severity Differential diagnosis Butler et al. Pain. 2007

19 Learning Objectives Explain how pain and opioid use disorder (OUD) activate the same neurobiological pathways in the brain Recognize that differentiating opioid use disorder from pain is a complex task Identify ways to improve pain treatment in patients with opioid use disorders

20 Pain Treatment in Opioid Use Disorder Engage patient General Principles Treat pain safely and effectively Address opioid use disorder Counseling and medication may be needed Address pain facilitators including substance withdrawal

21 Listen to and Engage Patient Past experiences can shape treatment choices Perceptions and expectations of treatment efficacy impacts outcomes Investment in plan facilitates cooperation Plan treatment when pain anticipated Engagement in self-management critical to chronic pain treatment, helpful for all pain Focus on non-medication modalities

22 Treat Pain Safely and Effectively Reduce or resolve underlying pain causes when possible Provide appropriate pain relief Non-medication approaches when effective, safe, easily available and acceptable to patient Less-rewarding meds when safe and effective Potentially rewarding medications when needed with appropriate limits on use Plan treatment when pain anticipated (eg for elective procedures or surgery)

23 Address Pain Facilitators Commonly: Acute pain Anxiety, PTSD, sleep disturbance, substance issues, substance withdrawal (particularly opioid withdrawal) Chronic non-cancer pain Anxiety, PTSD, sleep disturbance, substance issues, depression, functional losses, learning, and reward Terminal pain Anxiety, PTSD, sleep disturbance, substance issues, depression, functional losses, spiritual challenges, grief over impending losses

24 Address Opioid Use Disorder Acknowledge the challenge Assure not an obstacle to working for analgesia Encourage and support recovery Discuss what has been valuable for patient Identify or intensify psychosocial support Substance use counselor, self help groups, sponsor, faith-based interventions, mindfulness, etc. Continue or offer pharmacologic support like methadone or buprenorphine Assure safety: limited access and supply 3 to 5 day supply of opioids, if prescribed

25 Address Opioid Use Disorder Treat withdrawal as appropriate Recognize that if you do not treat withdrawal safely and effectively, pain will never be treated Options: Methadone or Buprenorphine in hospital Outpatient: Buprenorphine only Opioid Treatment Program: Methadone Anticipate opioid tolerance in opioid-dependent individuals Be aware of opioid reward effects

26 Address Opioid Use Disorder Use Medication Treatment Options methadone and buprenorphine Versus very careful monitoring of IR medication for a limited time In acute pain, focus on relief in the initial period* BEWARE the Opioid Debt Do not fall trap to the initial period that never ends. Transient reward won t likely affect long-term course of opioid use disorder

27 CASE 35 yo female with chronic daily migraine and diffuse myofascial pain who has been prescribed opioids for 5 years after the birth of her daughter. The patient has severe depression and anxiety, chronic nausea, history of adverse childhood experience (neglect as a child), and obesity. She is a stay at home mother to her 2 children, but frequently has to put the children in daycare because she can not care for them when she has severe migraines. She is also prescribed chronic high dose benzodiazepines by a psychiatrist. She has been cited by the hospital as a frequent utilizer of services due to recurrent ED visits for nausea, vomiting, and severe migraine. The patient has a history of losing her opioid prescription, obtaining opioids from another provider, being allergic to most other pain medication options, missing appointments, and frequently asking for opioid dose increases.

28 Case: Thought Questions Does this patient have pain? Yes Does this patient have an opioid use disorder? Yes What factors place this patient at risk for an opioid use disorder? Young age, adverse childhood experience, mental illness, opioid exposure What can you do to help this patient? Provide referral for treatment and/or medication treatment, patient would likely respond well to medication treatment for her opioid use disorder

29 Same Case Patient gets referred for a Nissen fundoplication given severe gastritis and concern for ongoing ulcer disease. Patient is very concerned about pain relief after the procedure. Approach: Speak with treatment provider Plan pain management for a limited time per expected recovery Limit Rx at discharge and refer back to treatment Patient will very well need methadone or buprenorphine, if not already on the medication

30 Thank you!

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St.

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners, Albany, NY Assistant Professor of Medicine,

More information

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Daniel Warren, MD Eastern Oregon Coordinated Care Organization Provider Forum on Chronic Noncancer Pain Management Pendleton, OR February 24,

More information

Neurobiology of Addiction

Neurobiology of Addiction Neurobiology of Addiction Tiffany Love, Ph.D. Department of Psychiatry The University of Utah What is Addiction? Addiction is a chronic, relapsing, and treatable brain disorder. Compulsive drug seeking

More information

Opioids for Pain Treatment in Persons with Opioid Use Disorder. Patricia Pade, MD Seddon R. Savage, MD, MS Melissa Weimer, DO, MCR

Opioids for Pain Treatment in Persons with Opioid Use Disorder. Patricia Pade, MD Seddon R. Savage, MD, MS Melissa Weimer, DO, MCR Opioids for Pain Treatment in Persons with Opioid Use Disorder Patricia Pade, MD Seddon R. Savage, MD, MS Melissa Weimer, DO, MCR 1 Educational Objectives At the conclusion of this activity participants

More information

BASIC VOLUME. Elements of Drug Dependence Treatment

BASIC VOLUME. Elements of Drug Dependence Treatment BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop

More information

Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP

Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Disclosures This speaker has no conflicts of interest to disclose Objectives Define drug abuse and addiction Identify the

More information

What are Substance Use Disorders?

What are Substance Use Disorders? What are Substance Use Disorders? Sanchit Maruti, MD Michael Goedde, MD University of Vermont Medical Center 1 Disclosures } Drs. Maruti and Goedde receive compensation as consultants to the American Academy

More information

Understanding Addiction: Why Can t Those Affected Just Say No?

Understanding Addiction: Why Can t Those Affected Just Say No? Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions

More information

Learning Objectives. A Patient to Keep Us Company. Introduction to Addiction Medicine: Root Causes and Lived Experience 3/3/2015

Learning Objectives. A Patient to Keep Us Company. Introduction to Addiction Medicine: Root Causes and Lived Experience 3/3/2015 Introduction to Addiction Medicine: Root Causes and Lived Experience Daren Ford, LCSW, CADC II Rachel Solotaroff, MD, MCR Learning Objectives Increase knowledge and understanding of substance use Engage

More information

Opioid Overdose Epidemic A Crises and Opportunity

Opioid Overdose Epidemic A Crises and Opportunity Opioid Overdose Epidemic A Crises and Opportunity Samuel M. Silverman MD, FAPA, DFASAM Assistant Clinical Professor, UConn Medical School Director, Medical Education Rushford, A Hartford HealthCare Partner

More information

Council on Chemical Abuse Annual Conference November 2, The Science of Addiction: Rewiring the Brain

Council on Chemical Abuse Annual Conference November 2, The Science of Addiction: Rewiring the Brain Council on Chemical Abuse Annual Conference November 2, 2017 The Science of Addiction: Rewiring the Brain David Reyher, MSW, CAADC Behavioral Health Program Director Alvernia University Defining Addiction

More information

CHAPTER 2. THE NEUROBIOLOGY OF SUBSTANCE USE, MISUSE, AND ADDICTION

CHAPTER 2. THE NEUROBIOLOGY OF SUBSTANCE USE, MISUSE, AND ADDICTION CHAPTER 2. THE NEUROBIOLOGY OF SUBSTANCE USE, MISUSE, AND ADDICTION Chapter 2 Preview A substantial body of research has accumulated over several decades and transformed our understanding of substance

More information

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful

More information

Opioid Epidemic Update

Opioid Epidemic Update Opioid Epidemic Update - 2018 Talal Khan MD Addiction Psychiatrist Pine Rest What are Opioids? Opiates are alkaloid compounds naturally found in the opium Poppy plant. Papaver somniferum The psychoactive

More information

590,000 deaths can be attributed to an addictive substance in some way

590,000 deaths can be attributed to an addictive substance in some way Mortality and morbidity attributable to use of addictive substances in the United States. The Association of American Physicians from 1999 60 million tobacco smokers in the U.S. 14 million dependent on

More information

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Myth or Reality? Complete Recovery means a medication-free state True or False? Treatment of Alcoholism Assessment Motivation Alcohol

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Basics of Benzodiazepine Use Disorder. DATE: October 3, 2017 PRESENTED BY: Melissa B. Weimer, DO, MCR

Basics of Benzodiazepine Use Disorder. DATE: October 3, 2017 PRESENTED BY: Melissa B. Weimer, DO, MCR Basics of Benzodiazepine Use Disorder DATE: October 3, 2017 PRESENTED BY: Melissa B. Weimer, DO, MCR Disclosures Speaker disclosure: One time lecture sponsored by Indivior about overlap of pain and opioid

More information

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.

More information

Effects of Drugs on the Brain and Behavior in Adolescents

Effects of Drugs on the Brain and Behavior in Adolescents Effects of Drugs on the Brain and Behavior in Adolescents Lucas Moore, LCSW, SAC-IT Adolescent Substance Abuse Treatment Coordinator July 20, 2015 Wisconsin Department of Health Services Today What would

More information

MOLECULAR BIOLOGY OF DRUG ADDICTION. Sylvane Desrivières, SGDP Centre

MOLECULAR BIOLOGY OF DRUG ADDICTION. Sylvane Desrivières, SGDP Centre 1 MOLECULAR BIOLOGY OF DRUG ADDICTION Sylvane Desrivières, SGDP Centre Reward 2 Humans, as well as other organisms engage in behaviours that are rewarding The pleasurable feelings provide positive reinforcement

More information

If you give any person a prescription of something like Valium and have them take it on

If you give any person a prescription of something like Valium and have them take it on As always I am happy to do this presentation, which is my favorite topic in addiction medicine. I am an internist, and I have done healthcare for the homeless in Springfield as well as been the medical

More information

Understanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO

Understanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO Understanding Addiction and Its Impact on the Brain SDSMA Webinar Matthew Stanley, DO Estimated Economic Cost to Society Due to Substance Abuse and Addiction: Illegal drugs: Alcohol: Tobacco: $181 billion/year

More information

The Opioid Epidemic and Youth Prescription Drug Abuse. Sandy Chung, MD Chair, Board of Trustees Virginia Foundation for Healthy Youth

The Opioid Epidemic and Youth Prescription Drug Abuse. Sandy Chung, MD Chair, Board of Trustees Virginia Foundation for Healthy Youth The Opioid Epidemic and Youth Prescription Drug Abuse Sandy Chung, MD Chair, Board of Trustees Virginia Foundation for Healthy Youth Disclosures: I have no relevant financial relationships with the manufacturer(s)

More information

Part IV: Slipping Up: Neuroscience Basis of Relapse & Recovery July 31, am 12:30 pm with Break 10-10:15am

Part IV: Slipping Up: Neuroscience Basis of Relapse & Recovery July 31, am 12:30 pm with Break 10-10:15am Eighth Edition Congratulations and Thank You All for Attending Part IV: Slipping Up: Neuroscience Basis of Relapse & Recovery July 31, 2015 8 am 12:30 pm with Break 10-10:15am Preventing Recrudescence

More information

Neurobiology of Addiction. Jon E. Grant, JD, MD, MPH Professor University of Chicago

Neurobiology of Addiction. Jon E. Grant, JD, MD, MPH Professor University of Chicago Neurobiology of Addiction Jon E. Grant, JD, MD, MPH Professor University of Chicago Disclosure Information I have the following financial relationships to disclose: My research is supported by NIDA, AFSP,

More information

The Chronic Disease of Addiction Evidence and Lessons from Practice

The Chronic Disease of Addiction Evidence and Lessons from Practice The Chronic Disease of Addiction Evidence and Lessons from Practice Laura G. Kehoe, MD, MPH Medical Director, MGH Substance Use Disorders Unit Bridge Clinic Massachusetts General Hospital Assistant Professor

More information

The Neurobiology of Addiction. Angela Haliburda, DO

The Neurobiology of Addiction. Angela Haliburda, DO The Neurobiology of Addiction Angela Haliburda, DO Currently, 8-10% of those age 12+ years, or 20 million to 22 million Americans are addicted to alcohol or other drugs. Drug overdoses are now the leading

More information

The Biology of Addiction

The Biology of Addiction The Biology of Addiction Risk factors for addiction: Biological/Genetic Family history of addiction Being male Having mental illness Exposure to substances in utero * The genes that people are born with

More information

Addiction. Concept of Addiction R. Corey Waller MD, MS, FACEP, FASAM Director, Center for Integrative Medicine

Addiction. Concept of Addiction R. Corey Waller MD, MS, FACEP, FASAM Director, Center for Integrative Medicine Addiction Concept of Addiction R. Corey Waller MD, MS, FACEP, FASAM Director, Center for Integrative Medicine Twitter: @rcwallermd Objectives Understand the Concept of Addiction Survival FOOD WATER DOPAMINE

More information

Tapering Opioids Best Practices*

Tapering Opioids Best Practices* Tapering Opioids Best Practices* Chuck Hofmann, MD, MACP 5 th Annual EOCCO Office Staff and Provider Summit September 28, 2017 Disclosure No Conflicts of Interest to report Learning Objectives Understand

More information

Effectively Addressing Co-Occurring Nicotine Dependence and Marijuana Use. Chad Morris, PhD March 7, 2018

Effectively Addressing Co-Occurring Nicotine Dependence and Marijuana Use. Chad Morris, PhD March 7, 2018 Effectively Addressing Co-Occurring Nicotine Dependence and Marijuana Use Chad Morris, PhD March 7, 2018 2018 BHWP Behavioral Causes of Death in U.S. 2018 BHWP 2018 BHWP Health Disparities Population Behavioral

More information

ADDICTION OBJECTIVES 4/10/2018 DISCLOSURE

ADDICTION OBJECTIVES 4/10/2018 DISCLOSURE ADDICTION Michael Baron, MD, MPH, FASAM Medical Director Tennessee Medical Foundation - Physician s Health Program DISCLOSURE I have no financial relationships to disclose. I will not discuss off label

More information

The Neurobiology of Addiction

The Neurobiology of Addiction The Neurobiology of Addiction Jodi Gilman, Ph.D. Center for Addiction Medicine Massachusetts General Hospital Associate Professor, Department of Psychiatry Harvard Medical School What is Addiction? commonly

More information

VIVITROL (naltrexone for extended-release injectable suspension) A µ-opioid Receptor Antagonist

VIVITROL (naltrexone for extended-release injectable suspension) A µ-opioid Receptor Antagonist MECHANISM OF ACTION VIVITROL (naltrexone for extended-release injectable suspension) A µ-opioid Receptor Antagonist VIVITROL is indicated for prevention of relapse to opioid dependence, following opioid

More information

ECHO Presentation Addiction & Brain Function

ECHO Presentation Addiction & Brain Function ECHO Presentation Addiction & Brain Function May 23 rd, 2018 Richard L. Bell, Ph.D. Associate Professor of Psychiatry Indiana University School of Medicine ribell@iupui.edu Development of Addiction Addiction

More information

Neurobiology of Substance and Gambling Addictions

Neurobiology of Substance and Gambling Addictions Neurobiology of Substance and Gambling Addictions Jon E. Grant, JD, MD, MPH Professor University of Chicago Disclosure Information I have the following financial relationships to disclose: My research

More information

Opioid Review and MAT Clinic CDC Guidelines

Opioid Review and MAT Clinic CDC Guidelines 1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are

More information

substance use and mental disorders: one, the other, or both?

substance use and mental disorders: one, the other, or both? substance use and mental disorders: one, the other, or both? Stephen Strobbe, PhD, RN, PMHCNS-BC, CARN-AP Dawn Farm Education Series St. Joe s Education Center, Ypsilanti, MI Tuesday, January 27, 2015

More information

At a Glance. Background Information. Lesson 3 Drugs Change the Way Neurons Communicate

At a Glance. Background Information. Lesson 3 Drugs Change the Way Neurons Communicate Lesson 3 Drugs Change the Way Neurons Communicate Overview Students build upon their understanding of neurotransmission by learning how different drugs of abuse disrupt communication between neurons. Students

More information

Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic

Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic Lucas Buffaloe, MD Associate Professor of Clinical Family and Community Medicine University of Missouri Health Care Goals for today

More information

Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine

Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine [Patient-focused, evidence-based addiction treatment] Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine BrightView Health All Rights Reserved www.brightviewhealth.com

More information

Possession by evil spirits? Demon rum. Lack of moral fiber? War on drugs Just say no

Possession by evil spirits? Demon rum. Lack of moral fiber? War on drugs Just say no Dr. Joseph Garbely Medical Director VP of Medical Services Caron Treatment Centers 1 ASAM Disclosure of Relevant Financial Relationships No Relevant Financial Relationships with Any Commercial Interests

More information

Universal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids?

Universal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids? Learning objectives 1. Identify the contribution of psychosocial and spiritual factors to pain 2. Incorporate strategies for identifying and mitigating opioid misuse 3. Incorporate non-pharmaceutical modalities

More information

Substance Use Disorders: brains, behavior, and diagnosis. Jessica Gregg, MD, PhD OHSU Addiction Medicine Section

Substance Use Disorders: brains, behavior, and diagnosis. Jessica Gregg, MD, PhD OHSU Addiction Medicine Section Substance Use Disorders: brains, behavior, and diagnosis Jessica Gregg, MD, PhD OHSU Addiction Medicine Section Disclosures Nothing to disclose 2 Objectives 1. Review the diagnostic criteria for substance

More information

John Murphy DO, MS Lynx Healthcare

John Murphy DO, MS Lynx Healthcare Addiction to Pain Medication and Treatment John Murphy DO, MS Lynx Healthcare No Disclosures Objectives 1 Understand basic neurobiology and learning theory around opioid addiction 2 Identify aberrant behavior

More information

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to

More information

Neurobiology of Pain and Addiction

Neurobiology of Pain and Addiction T. Celeste Napier, Ph.D. Neurobiology of Pain and Addiction Focus on Opioids Professor, Department of Psychiatry Director, Center for Compulsive Behavior and Addiction Disclosures In the past three years,

More information

ADHD & Addictions -What We Know

ADHD & Addictions -What We Know ADHD & Addictions -What We Know Dr. David Teplin, Psy.D., C.Psych. 4th CADDAC Annual Conference, Toronto October 14, 2012 1 Introduction Adult ADHD commonly co-exists with several other disorders, including

More information

Medication Assisted Treatment. Nicole Gastala, MD

Medication Assisted Treatment. Nicole Gastala, MD Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants

More information

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives

More information

Effects of Prenatal Illicit Drug. Use on Infant and Child

Effects of Prenatal Illicit Drug. Use on Infant and Child Effects of Prenatal Illicit Drug Use on Infant and Child Development Andrew Hsi, MD, MPH Larry Leeman, MD, MPH Family Medicine MCH Grand Rounds 6 July 2011 Objectives for Presentation At the end of this

More information

Brain Health and Opioid Abuse

Brain Health and Opioid Abuse 2018 Statewide Tribal Opioid Summit Brain Health and Opioid Abuse Healing From Opiate Addiction Requires Comprehensive Approaches Psychological, Socio-Cultural, and Biological Donald R. Vereen, Jr., M.D.,

More information

BRAIN MECHANISMS OF REWARD AND ADDICTION

BRAIN MECHANISMS OF REWARD AND ADDICTION BRAIN MECHANISMS OF REWARD AND ADDICTION TREVOR.W. ROBBINS Department of Experimental Psychology, University of Cambridge Many drugs of abuse, including stimulants such as amphetamine and cocaine, opiates

More information

MAT in the Corrections Setting

MAT in the Corrections Setting MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on

More information

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5

More information

Pain Management and Addiction: Clinical Challenges

Pain Management and Addiction: Clinical Challenges Pain Management and Addiction: Clinical Challenges MMS Pain Management Forum March 12, 2010 Associate Professor of Medicine Boston University School of Medicine Boston Medical Center Conflicts of Interest

More information

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures

More information

processes in the central nervous system (CNS), affecting many of the during the course of ethanol treatment. Ethanol stimulates the release of

processes in the central nervous system (CNS), affecting many of the during the course of ethanol treatment. Ethanol stimulates the release of INTRODUCTION INTRODUCTION Neuroscience research is essential for understanding the biological basis of ethanol-related brain alterations and for identifying the molecular targets for therapeutic compounds

More information

National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says

National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says Last Updated February 2016 https://www.drugabuse.gov 1 Table of Contents Understanding Drug Abuse and Addiction:

More information

OPIOID ADDICTION AND THE BRAIN MICHAEL NERNEY AND ASSOCIATES P.O. BOX 93 LONG LAKE, NY

OPIOID ADDICTION AND THE BRAIN MICHAEL NERNEY AND ASSOCIATES P.O. BOX 93 LONG LAKE, NY OPIOID ADDICTION AND THE BRAIN MICHAEL NERNEY AND ASSOCIATES P.O. BOX 93 LONG LAKE, NY 12847-0093 518-624-5351 MCNERNEYLL@FRONTIERNET.NET A DISEASE OF THE BRAIN ASAM Primary chronic disease of the brain

More information

Psychotropic Drugs Critical Thinking - KEY

Psychotropic Drugs Critical Thinking - KEY Open Your Class with This Tomorrow Chasing the Scream: The First and Last Days of the War on s Psychotropic s Critical Thinking - KEY Background: The blood-brain barrier is a network of tightly packed

More information

Basic definition and Classification of Anhedonia. Preclinical and Clinical assessment of anhedonia.

Basic definition and Classification of Anhedonia. Preclinical and Clinical assessment of anhedonia. Basic definition and Classification of Anhedonia. Preclinical and Clinical assessment of anhedonia. Neurobiological basis and pathways involved in anhedonia. Objective characterization and computational

More information

Addiction in the Brain - Latest Research. Gary M. Henschen, MD, LFAPA Chief Behavioral Health Officer Magellan Healthcare, Inc.

Addiction in the Brain - Latest Research. Gary M. Henschen, MD, LFAPA Chief Behavioral Health Officer Magellan Healthcare, Inc. Addiction in the Brain - Latest Research Gary M. Henschen, MD, LFAPA Chief Behavioral Health Officer Magellan Healthcare, Inc. The Neurobiology of Addiction About the speaker Gary M. Henschen, M.D. is

More information

Brain Imaging studies in substance abuse. Jody Tanabe, MD University of Colorado Denver

Brain Imaging studies in substance abuse. Jody Tanabe, MD University of Colorado Denver Brain Imaging studies in substance abuse Jody Tanabe, MD University of Colorado Denver NRSC January 28, 2010 Costs: Health, Crime, Productivity Costs in billions of dollars (2002) $400 $350 $400B legal

More information

2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society

2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society Pregnant Women Who Use Drugs: Stigma, Science and Society Mishka Terplan MD MPH FACOG FASAM Professor Departments Obstetrics and Gynecology and Psychiatry Associate Director Addiction Medicine Virginia

More information

Learning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons

Learning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons Marianna Corona Jennifer Foley September 12, 2017 Learning Objectives 2017 Improving Family Outcomes

More information

Module Two: Pharmacotherapies for Opioid Substitution Treatment

Module Two: Pharmacotherapies for Opioid Substitution Treatment Module Two: Pharmacotherapies for Opioid Substitution Treatment Neurobiology of Addiction Pharmacology of Opioids Methadone Buprenorphine Pharmacokinetics of Methadone & Buprenorphine Opioid effects Intoxication

More information

What do they have in common?

What do they have in common? What do they have in common? Opioid use in USA Approximately 9 million people on long term opioids Approximated 5 million people reporting non-medical use of opioids 1997: 96mg/person morphine eq dispensed

More information

Basics of Benzodiazepine Use Disorder. DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR

Basics of Benzodiazepine Use Disorder. DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR Basics of Benzodiazepine Use Disorder DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR Disclosures Speaker: Melissa Weimer, DO, MCR, has nothing to disclose. Planning Committee: The members

More information

Adult 65D-30 Intervention ASAM Level.05 DIMENSIONS Circle all items in each dimension that apply to the client. ADMISSION CRITERIA

Adult 65D-30 Intervention ASAM Level.05 DIMENSIONS Circle all items in each dimension that apply to the client. ADMISSION CRITERIA Adult 65D-30 Intervention ASAM Level.05 ADMISSION CRITERIA Place a check in the yes or no box that indicates validation or lack ASAM Requirements Withdrawal and of validation for placement into this level

More information

Key Concepts. Machinery of the Mind. The Growing Cycle. Six Brain Mind Functions. Machinery of the Mind 6/1/2012

Key Concepts. Machinery of the Mind. The Growing Cycle. Six Brain Mind Functions. Machinery of the Mind 6/1/2012 Machinery of the Mind How High-risk Choices Redesign the Brain Key Concepts Brain and Mind are reciprocal Brain/Mind Functions intertwine We are hardwired and we have software Your brain changes all the

More information

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016 What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)

More information

ASAM Level.05 DIMENSIONS Circle all items in each dimension that apply to the client. ADMISSION CRITERIA

ASAM Level.05 DIMENSIONS Circle all items in each dimension that apply to the client. ADMISSION CRITERIA Print Client Name: Client Identification Number: Date: Adolescent 65D-30 Intervention ASAM Level.05 ADMISSION CRITERIA Acute Intoxication and /or Withdrawal Biomedical Conditions and of validation for

More information

Talking with your doctor

Talking with your doctor SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may

More information

SAFE PRESCRIBING: RULES AND REGULATIONS. Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017

SAFE PRESCRIBING: RULES AND REGULATIONS. Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017 SAFE PRESCRIBING: RULES AND REGULATIONS Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017 DISCLOSURES I have no financial disclosures. OBJECTIVES Discuss the significance of the opiate

More information

NEUROBIOLOGY ALCOHOLISM

NEUROBIOLOGY ALCOHOLISM NEUROBIOLOGY ALCOHOLISM THERE HAS BEEN A MAJOR THEORETICAL SHIFT IN MEDICATION DEVELOPMENT IN ALCOHOLISM Driven by animal models of intermittent ethanol administration followed by termination, then access

More information

Intro to Concurrent Disorders

Intro to Concurrent Disorders CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,

More information

Dr. Meldon Kahan. Women s College Hospital. with PIA LAW

Dr. Meldon Kahan. Women s College Hospital. with PIA LAW with PIA LAW and Toronto ABI Network Dr. Meldon Kahan Women s College Hospital Dr. Meldon Kahan is an Associate Professor in the Department of Family Medicine at University of Toronto, and Medical Director

More information

THE STATE OF MEDICINE IN ADDICTION RECOVERY

THE STATE OF MEDICINE IN ADDICTION RECOVERY OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,

More information

Mental Health First Aid at a Glance

Mental Health First Aid at a Glance Mental Health First Aid at a Glance Candice M. Haines, LCPC Program Supervisor Mental Health First Aid Instructor Pilsen Wellness Center chaines@pilsenmh.org Overview Address myths vs facts Warning signs

More information

Knock Out Opioid Abuse in New Jersey:

Knock Out Opioid Abuse in New Jersey: Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids

More information

Subject: Pain Management (Page 1 of 7)

Subject: Pain Management (Page 1 of 7) Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all

More information

The Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome

The Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome Neonatal Nursing Education Brief: The Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome https://www.seattlechildrens.org/healthcareprofessionals/education/continuing-medical-nursing-education/neonatalnursing-education-briefs/

More information

Pain and Addiction. Edward Jouney, DO Department of Psychiatry

Pain and Addiction. Edward Jouney, DO Department of Psychiatry Pain and Addiction Edward Jouney, DO Department of Psychiatry Case 43 year-old female with a history chronic lower back pain presents to your clinic ongoing care. She has experienced pain difficulties

More information

California. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Relationships Relationships

Relationships Relationships PRENATAL OPIATE EXPOSURE IMPACT ON EARLY CHILDHOOD LEARNING AND BEHAVIOR Ira J. Chasnoff, MD NTI Upstream www.ntiupstream.com Children grow and develop in the context of Attachment: Basic Concept Attachment:

More information

Neurobiology of addiction and why it is important

Neurobiology of addiction and why it is important Neurobiology of addiction and why it is important Stephen Jurd University of Sydney 2016 IF Addiction has a neurobiological basis THEN we should be able to: Define addiction AND Identify relevant neurological

More information

11/7/2016. Possession by evil spirits? Demon rum. Lack of moral fiber? War on drugs Just say no

11/7/2016. Possession by evil spirits? Demon rum. Lack of moral fiber? War on drugs Just say no Dean Drosnes, MD, FASAM Associate Medical Director Caron Treatment Centers ASAM Disclosure of Relevant Financial Relationships Date of Activity: Nov 3, 2016 Name Commercial Interests Relevant Financial

More information

Topics of today s training

Topics of today s training Extended Release Naltrexone Vivitrol Christopher J Davis D.O. CAADC, FASAM Medical Director, Brightwater Landing Medical Director, Pyramid Healthcare Diplomate of The American Board of Addition Medicine

More information

The Neuroscience of Addiction: A mini-review

The Neuroscience of Addiction: A mini-review The Neuroscience of Addiction: A mini-review Jim Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital Disclosures Neither I nor my spouse/partner has a relevant financial relationship

More information

Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management. Melissa Weimer, DO, MCR Oregon Health & Science University

Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management. Melissa Weimer, DO, MCR Oregon Health & Science University Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management Melissa Weimer, DO, MCR Oregon Health & Science University 1 Educational Objectives At the conclusion of this activity participants

More information

Jerry Cochran, MSW, PhD University of Utah School of Medicine Department of Internal Medicine Department of Psychiatry

Jerry Cochran, MSW, PhD University of Utah School of Medicine Department of Internal Medicine Department of Psychiatry Jerry Cochran, MSW, PhD University of Utah School of Medicine Department of Internal Medicine Department of Psychiatry Acknowledgements Funding for this work has come from: The Staunton Farm Foundation

More information

DSM-5 AND ASAM CRITERIA. Presented by Jaime Goffin, LCSW

DSM-5 AND ASAM CRITERIA. Presented by Jaime Goffin, LCSW DSM-5 AND ASAM CRITERIA Presented by Jaime Goffin, LCSW MODULE 1: GOALS & OBJECTIVES What is your experience with using ASAM and DSM 5 criteria? What are your learning expectations for today? GOAL FOR

More information

Eighth Edition. Part I: Current Science of Addiction, Relapse & Recovery: Dispelling The Stigmas

Eighth Edition. Part I: Current Science of Addiction, Relapse & Recovery: Dispelling The Stigmas Eighth Edition Part I: Current Science of Addiction, Relapse & Recovery: Dispelling The Stigmas 1 < < < Evolution of our Human Brain: Spinal Cord to Diencephalon to Mammalian-Meso Cortex to Neo Cortex

More information

Substance Use Disorders: What Can We Do to Help Break the Cycle of Addiction

Substance Use Disorders: What Can We Do to Help Break the Cycle of Addiction Handout for the Neuroscience Education Institute (NEI) online activity: Substance Use Disorders: What Can We Do to Help Break the Cycle of Addiction Learning Objectives Identify patients who are dependent

More information

ASAM Criteria, Third Edition Matrix for Matching Adult Severity and Level of Function with Type and Intensity of Service

ASAM Criteria, Third Edition Matrix for Matching Adult Severity and Level of Function with Type and Intensity of Service 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 0 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 1 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 2 The patient

More information

Supported by the Indiana Public Health Training Center. Welcome We will begin shortly

Supported by the Indiana Public Health Training Center. Welcome We will begin shortly Supported by the Indiana Public Health Training Center Welcome We will begin shortly Public Health Insights and Innovations Self-Claim Attendance Please text code 42223 to 317-671-8998 to record your attendance

More information

Presented by Dr. Craig Strickland

Presented by Dr. Craig Strickland Presented by Dr. Craig Strickland https://sites.google.com/site/bioedcon strickkat@verizon.net List three psychosocial factors that can influence the development of addiction in the elderly Summarize basic

More information

WHEN LESS IS MORE REDUCING OPIOID OVERPRESCRIBING

WHEN LESS IS MORE REDUCING OPIOID OVERPRESCRIBING WHEN LESS IS MORE REDUCING OPIOID OVERPRESCRIBING Maria Foy, PharmD, BCPS, CPE Pharmacy Care Coordinator, Palliative Care Abington Hospital Jefferson Health Goals and Objectives Describe how opioid overprescribing

More information